In kind
19 June 2008

The drug giant inked an agreement that postpones generic competition to its $12bn cholesterol drug from India s Ranbaxy. The quid pro quo: Ranbaxy can sell another of Pfizer s drugs. This may not be as obviously anticompetitive as a cash payment, but it s close.